Thompson Davis & Co’s Gyre Therapeutics GYRE Stock Holding History

Thompson Davis & Co’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17	Closed	-$3K	–	698
2018 Q1	$3K	Hold	17	–	–	0.01%	542
2017 Q4	$2K	Buy	+17	New	+$867	﹤0.01%	603
2015 Q2	–	Sell	-18	Closed	-$42K	–	1210
2015 Q1	$42K	Buy	+18	New	+$37.2K	0.05%	323

Other funds holding GYRE

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Thompson Davis & Co's GYRE Position: Q2 2018 in Review

Thompson Davis & Co sold out of Gyre Therapeutics (GYRE) in Q2 2018, closing a stake of 17 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in GYRE in Q1 2015 and held it in 3 quarters. The position peaked at $42K in Q1 2015. 75 funds tracked by Wall St. Rank hold GYRE as of Q2 2018.

Thompson Davis & Co reported no remaining Gyre Therapeutics position as of Q2 2018 after selling out during the quarter.
Thompson Davis & Co sold 17 Gyre Therapeutics shares in Q2 2018, an estimated $3K.
Thompson Davis & Co first reported a position in Gyre Therapeutics in Q1 2015 and held it in 3 quarters.
Thompson Davis & Co's Gyre Therapeutics position peaked at $42K in Q1 2015.
75 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2018.

Based on Thompson Davis & Co's 13F filing for Q2 2018, filed 3 Aug 2018.